• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us

Post-Marketing Surveillance

Home / What We Do / Post-Marketing Surveillance

Post-Marketing Surveillance

Post-marketing surveillance (PMS) refers to the collection of safety and/or efficacy data once a new therapy has received marketing authorisation (or conditional marketing authorisation). This is often mandated by medicines regulators and allows for the collection of long-term data in the clinical setting.

The wide expertise within TREAT-NMD allow us to contribute to post-marketing studies as an independent partner to pharmaceutical companies or clinical research organisations.

We work alongside our registry network and project partners to facilitate access to data that offers accurate and reliable measures of patient health and wellbeing.

TREAT-NMD is fully GDPR compliant, and our infrastructure is regulatory compliant. Our project management team, who have significant commercial and scientific experience, are responsible for TREAT-NMD’s role in post-marketing studies, and operate a flexible hybrid Prince2 project methodology.

We are proud to work with the Life Sciences Industry and Clinical Research Organisations in the design and management of robust and effective processes for PMS.  Our collaborations ensure that safe and efficacious treatments for rare neuromuscular diseases will reach patient populations to improve health and quality of life for patients and their families.

Primary Sidebar

  • What We Do
  • Advisory Committee for Therapeutics
    • Advisory Committee for Therapeutics
    • Members of the Advisory Committee for Therapeutics
    • The Report
  • Global Registry Network
    • The Global Registry Network
    • Global Data systems Oversight Committee – TGDOC
    • Members of the Registry Network
  • Core Datasets
    • Core Datasets
    • DM dataset
    • DMD dataset
    • FSHD dataset
    • LGMD dataset
    • SMA dataset
  • Education
    • Education
    • Masterclasses
    • E-learning Platform
    • Endorsement of external programmes
  • Post-Marketing Surveillance
    • Post-Marketing Surveillance
    • STRIDE Registry

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter sign up

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • The Report
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Back